REAL-WORLD TREATMENT PATTERNS ACROSS FIRST-, SECOND- AND THIRD-LINE THERAPY IN METASTATIC COLORECTAL CANCER (MCRC): RESULTS FROM DANISH NATIONAL REGISTER DATA
Author(s)
Jacob Elskær Mollerup, MS1, Alexandra Wennberg, PhD2, Kristian Burr Kreiberg, MD3, Per Pfeiffer, MD, PhD3, Johan Liseth Hansen, PhD4.
1Quantify Research, Copenhagen, Denmark, 2Quantify Research, Stockholm, Sweden, 3Syddansk Universitet, Odense, Denmark, 4Quantify Research, Oslo, Norway.
1Quantify Research, Copenhagen, Denmark, 2Quantify Research, Stockholm, Sweden, 3Syddansk Universitet, Odense, Denmark, 4Quantify Research, Oslo, Norway.
OBJECTIVES: To assess Real-World (RW) treatment patterns in patients with mCRC first (1L) through third line (3L) in a nation-wide Danish cohort.
METHODS: A treatment algorithm was applied to patients diagnosed with mCRC (ICD-10: C18-C20, stage IV) 2017-2024 in the Danish Cancer Register. 1L regimens were captured 90 days of diagnosis using a 60-day window from first systemic treatment. Subsequent lines (2L, 3L) used 45-day windows. Significant treatment add-ons or switches defined line advancement, preventing repeated treatment regimens. Patients were followed until emigration, death, or June 30, 2025.
RESULTS: Among 7,202 patients with mCRC, median age was 72 years and 61.5% had >2 metastatic sites. Overall, 53.6% initiated 1L treatment, of whom 47.6% and 20.3% progressed to 2L and 3L treatment, respectively. Common1L chemotherapy (CT) regimens include FOLFIRI (44.6%), CapOx (15.6%) and FOLFOX (6.7%). CT regimens in combination with a targeted anti-EGFR or with an anti-VEgF made up 15.0% and 4.4% of treatments, respectively, while CT triplets, FOLFOXIRI, were given to 6.4%. 2L treatment showed similar combinatory patterns, with greater use of oxaliplatin- (47.7%) than irinotecan-based (37.1%) CT backbones. 3L treatment primarily consisted of irinotecan-based treatment options (44.9%), of which 70% were in combination with an anti-EGFR or anti-VEgF agent. FTD/TPI with bevacizumab as latest SoC in 3L was administered to 5.5%.
CONCLUSIONS: Combination chemotherapy predominated across lines, with core regimens shifting between oxaliplatin- and irinotecan-based therapies. Attrition between lines was substantial, highlighting the need for effective new treatment options. Treatment sequencing broadly followed national guideline recommendations.
METHODS: A treatment algorithm was applied to patients diagnosed with mCRC (ICD-10: C18-C20, stage IV) 2017-2024 in the Danish Cancer Register. 1L regimens were captured 90 days of diagnosis using a 60-day window from first systemic treatment. Subsequent lines (2L, 3L) used 45-day windows. Significant treatment add-ons or switches defined line advancement, preventing repeated treatment regimens. Patients were followed until emigration, death, or June 30, 2025.
RESULTS: Among 7,202 patients with mCRC, median age was 72 years and 61.5% had >2 metastatic sites. Overall, 53.6% initiated 1L treatment, of whom 47.6% and 20.3% progressed to 2L and 3L treatment, respectively. Common1L chemotherapy (CT) regimens include FOLFIRI (44.6%), CapOx (15.6%) and FOLFOX (6.7%). CT regimens in combination with a targeted anti-EGFR or with an anti-VEgF made up 15.0% and 4.4% of treatments, respectively, while CT triplets, FOLFOXIRI, were given to 6.4%. 2L treatment showed similar combinatory patterns, with greater use of oxaliplatin- (47.7%) than irinotecan-based (37.1%) CT backbones. 3L treatment primarily consisted of irinotecan-based treatment options (44.9%), of which 70% were in combination with an anti-EGFR or anti-VEgF agent. FTD/TPI with bevacizumab as latest SoC in 3L was administered to 5.5%.
CONCLUSIONS: Combination chemotherapy predominated across lines, with core regimens shifting between oxaliplatin- and irinotecan-based therapies. Attrition between lines was substantial, highlighting the need for effective new treatment options. Treatment sequencing broadly followed national guideline recommendations.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO120
Topic
Clinical Outcomes, Epidemiology & Public Health, Real World Data & Information Systems
Disease
Oncology